Breaking News Instant updates and real-time market news.

FGEN

FibroGen

$52.45

1.35 (2.64%)

16:04
05/21/18
05/21
16:04
05/21/18
16:04

FibroGen announces updated results from PRAISE study at ATS

FibroGen announced that updated results from the company's randomized, double-blind, placebo-controlled Phase 2b PRAISE study of pamrevlumab in patients with idiopathic pulmonary fibrosis, or IPF, were presented in several poster presentations at the American Thoracic Society, or ATS 2018. In total, the company is presenting four abstracts on pamrevlumab. Pamrevlumab, a proprietary first-in-class antibody targeting connective tissue growth factor, or CTGF, currently being developed for the treatment of fibrotic and fibroproliferative disorders, has demonstrated favorable results in slowing disease progression as measured by forced vital capacity, or FVC in IPF patients in two Phase 2 trials. The poster presentation at ATS presents additional results demonstrating that pamrevlumab treatment achieved a statistically significant reduced rate of progression of lung fibrosis compared to placebo using quantitative high resolution computed tomography, or HRCT. The pamrevlumab findings are consistent with reported results from a prior Phase 2 study in IPF. Quantitative lung fibrosis, or QLF measurements appear to be an objective method for quantifying the change in lung fibrosis captured by HRCT. In PRAISE, the change in QLF volumes in pamrevlumab-treated patients over 48 weeks was significantly less than in patients on placebo, and the treatment difference between pamrevlumab vs placebo was observed as early as six months. The change from baseline in QLF volume for pamrevlumab-treated patients was 24.8 ml vs 86.4 ml for placebo at Week 24, with a treatment difference of -61.6 ml. The change in QLF volume from baseline to 48 weeks was 75.4 ml in pamrevlumab-treated patients vs 151.5 ml from baseline to 48 weeks in patients on placebo, with a treatment difference of -76.2 ml. These QLF results on pamrevlumab's reduction of fibrotic build up in the lungs of IPF patients correlate with attenuation of the rate of decline in FVC % predicted, the primary endpoint of this study, with Spearman's correlation coefficient of -0.64. The PRAISE Phase 2b study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of pamrevlumab in patients with mild-to-moderate IPF. One hundred and three patients were randomized to receive either 30 mg/kg of pamrevlumab or placebo intravenously every three weeks. Lung function assessments were conducted at baseline and at Weeks 12, 24, 36, and 48. Quantitative HRCT assessments were performed at baseline and at Weeks 24 and 48. Additional secondary endpoints of the study were disease progression, health-related quality of life, and safety.

FGEN FibroGen
$52.45

1.35 (2.64%)

11/15/17
HCWC
11/15/17
NO CHANGE
Target $24
HCWC
Buy
Akebia recent selloff not based on fundamentals, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce notes that since the close on November 8, shares of FibroGen (FGEN) are down 17% while Akebia Therapeutics (AKBA) is down 21.3%. He attributes some of the weakness to FibroGen's Q3 earnings call, in which concerns arose that cardiovascular events in the large Phase 3 roxadustat cardiovascular outcomes trials are accruing too slowly. The analyst believes this has no fundamental bearing on Akebia or vadadustat, however. He keeps a Buy rating on the shares with a $24 price target.
12/18/17
PIPR
12/18/17
INITIATION
Target $26
PIPR
Overweight
Akebia initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.
02/28/18
LEER
02/28/18
NO CHANGE
Target $88
LEER
Outperform
FibroGen price target raised to $88 from $80 at Leerink
Leerink analyst Geoffrey Porges raised his price target for FibroGen to $88 from $80 after the company n reported Q4 financial and operational results, and provided updated later timing for the U.S. roxadustat phase III trials and approval in chronic kidney disease. The analyst reiterates an Outperform rating on the shares.
05/15/18
MZHO
05/15/18
UPGRADE
Target $61
MZHO
Buy
FibroGen upgraded to Buy from Neutral at Mizuho
Mizuho analyst Difei Yang upgraded FibroGen to Buy with an unchanged price target of $61. With a "solid" cash position, the company continues to make progress on its research and development pipeline, Yang tells investors in a research note. The analyst expects top-line Phase 3 data from Roxadustat in chronic kidney disease in Q4 and a potential regulatory approval in China is expected by year-end 2018. Yang believes believe FibroGen is likely to gain the first approval in new generation anemia drugs.

TODAY'S FREE FLY STORIES

ROSE

Rosehill Resources

$7.27

-0.235 (-3.13%)

13:09
06/18/18
06/18
13:09
06/18/18
13:09
Conference/Events
Rosehill Resources management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

FCE/A

Forest City Enterprises Inc

$0.00

(0.00%)

13:08
06/18/18
06/18
13:08
06/18/18
13:08
Hot Stocks
Breaking Hot Stocks news story on Forest City Enterprises Inc »

Forest City Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$58.62

0.18 (0.31%)

13:05
06/18/18
06/18
13:05
06/18/18
13:05
Options
Seagate call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCE/A

Forest City Enterprises Inc

$19.97

-0.04 (-0.20%)

13:02
06/18/18
06/18
13:02
06/18/18
13:02
Hot Stocks
Breaking Hot Stocks news story on Forest City Enterprises Inc »

Forest City Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCE.A

Forest City

$19.97

-0.04 (-0.20%)

, BAM

Brookfield

$41.31

-0.15 (-0.36%)

13:02
06/18/18
06/18
13:02
06/18/18
13:02
Periodicals
Breaking Periodicals news story on Forest City, Brookfield »

Forest City back in deal…

FCE.A

Forest City

$19.97

-0.04 (-0.20%)

BAM

Brookfield

$41.31

-0.15 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$152.48

-2.54 (-1.64%)

13:02
06/18/18
06/18
13:02
06/18/18
13:02
Hot Stocks
Vertex opens expanded research site in San Diego »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

AEP

American Electric

$65.21

0.16 (0.25%)

13:01
06/18/18
06/18
13:01
06/18/18
13:01
Hot Stocks
American Electric seeks bids for coal »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$7.68

-0.36 (-4.48%)

13:01
06/18/18
06/18
13:01
06/18/18
13:01
Hot Stocks
Insys Therapeutics provides update on ongoing transformation »

INSYS Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMSI

Merit Medical

$49.50

-0.6 (-1.20%)

12:55
06/18/18
06/18
12:55
06/18/18
12:55
Recommendations
Merit Medical analyst commentary  »

Merit Medical could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

12:55
06/18/18
06/18
12:55
06/18/18
12:55
General news
Treasury Action: yields rebounded from lows with stocks »

Treasury Action: yields…

NEWT

Newtek Business Services

$19.40

0.3 (1.57%)

12:54
06/18/18
06/18
12:54
06/18/18
12:54
Hot Stocks
Newtek Business Services raises 2018 annual dividend forecast to $1.72 per share »

Newtek Business Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

AAL

American Airlines

$42.36

-0.4 (-0.94%)

, LUV

Southwest

$52.02

-0.145 (-0.28%)

12:51
06/18/18
06/18
12:51
06/18/18
12:51
Periodicals
JetBlue founder plans to launch new airline, Airline Weekly reports »

JetBlue (JBLU) founder…

AAL

American Airlines

$42.36

-0.4 (-0.94%)

LUV

Southwest

$52.02

-0.145 (-0.28%)

UAL

United Continental

$74.18

0.29 (0.39%)

JBLU

JetBlue

$19.14

-0.05 (-0.26%)

DAL

Delta Air Lines

$54.77

-0.4 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 26

    Jul

XHB

SPDR Homebuilders

$40.50

-0.36 (-0.88%)

12:50
06/18/18
06/18
12:50
06/18/18
12:50
Options
Put buyers in SPDR Homebuilders ETF ahead of data »

Put buyers in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUNA

Luna Innovations

$3.01

-0.04 (-1.31%)

12:46
06/18/18
06/18
12:46
06/18/18
12:46
Hot Stocks
Breaking Hot Stocks news story on Luna Innovations »

Leviticus Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$16.65

0.69 (4.32%)

12:45
06/18/18
06/18
12:45
06/18/18
12:45
Options
Range Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

12:45
06/18/18
06/18
12:45
06/18/18
12:45
General news
Breaking General news story  »

Atlanta Federal Reserve…

SQ

Square

$65.15

0.595 (0.92%)

, TWTR

Twitter

$45.77

-0.03 (-0.07%)

12:43
06/18/18
06/18
12:43
06/18/18
12:43
Hot Stocks
Square moves higher after being granted cryptocurrency license in New York »

Shares of Square (SQ)…

SQ

Square

$65.15

0.595 (0.92%)

TWTR

Twitter

$45.77

-0.03 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

SJM

J.M. Smucker

$103.74

-1.95 (-1.85%)

12:35
06/18/18
06/18
12:35
06/18/18
12:35
Options
J.M. Smucker put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

AAPL

Apple

$188.89

0.02 (0.01%)

12:34
06/18/18
06/18
12:34
06/18/18
12:34
Periodicals
Apple Pay to launch in Poland on Tuesday, Cashless reports »

Apple Pay (AAPL) will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

GM

General Motors

$43.89

-0.02 (-0.05%)

12:29
06/18/18
06/18
12:29
06/18/18
12:29
Periodicals
GM to invest $175M to retool Michigan plant for Cadillac sedans, Reuters reports »

General Motors is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AWK

American Water

$81.42

0.36 (0.44%)

12:26
06/18/18
06/18
12:26
06/18/18
12:26
Hot Stocks
American Water investing over $14M to replace, install 48k feet of water main »

linois American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
06/18/18
06/18
12:25
06/18/18
12:25
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

BDX

Becton Dickinson

$229.87

-2.3 (-0.99%)

12:25
06/18/18
06/18
12:25
06/18/18
12:25
Conference/Events
Becton Dickinson has a conference call hosted by William Blair »

William Blair hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

AWK

American Water

$81.37

0.31 (0.38%)

12:24
06/18/18
06/18
12:24
06/18/18
12:24
Hot Stocks
American Water to invest $2.3M to upgrade 7,100 feet of water main in Pekin »

Illinois American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$14.70

2.675 (22.25%)

12:20
06/18/18
06/18
12:20
06/18/18
12:20
Options
Active trading in Rent A Center as shares rally »

Active trading in Rent A…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.